The Tip of the Iceberg of Misleading Online Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
Kim’s overview of Food and Drug Administration (FDA) regulatory actions from 2005 to 2014 is a comprehensive analysis of the US regulatory experience with online direct-to-consumer advertising (DTCA) of prescription medicines. This experience is of relevance internationally as online DTCA reaches th...
Main Author: | Barbara Mintzes |
---|---|
Format: | Article |
Language: | English |
Published: |
Kerman University of Medical Sciences
2016-05-01
|
Series: | International Journal of Health Policy and Management |
Subjects: | |
Online Access: | http://www.ijhpm.com/pdf_3164_3e1c9634f449a99e0f656966db8c6d57.html |
Similar Items
-
Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters
by: Hyosun Kim
Published: (2015-12-01) -
Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: Teaching Drug Marketers How to Inform Better or Spin Better?; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
by: Evan Doran
Published: (2016-05-01) -
Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
by: Brent L. Rollins
Published: (2016-04-01) -
Looking Beyond FDA Warning Letters to Explore Unforeseen Trouble Spots in eDTCA: A Response to Recent Commentaries
by: Hyosun Kim
Published: (2016-10-01) -
The Conundrum of Online Prescription Drug Promotion Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
by: Isaac Wanasika
Published: (2016-06-01)